Roche: Phase III SKYSCRAPER-02 Study In ES-SCLC Fails To Mee

SOUTH SAN FRANCISCO (dpa-AFX) - Swiss drug major Roche Holding AG (RHHBY) announced Wednesday that the phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer or ES-SCLC did not

Related Keywords

Switzerland , Swiss , , Drug Administration , Roche Holding , Breakthrough Therapy Designation , Roche , Hase , Skyscraper , Study , Clc , Nails , Feet , Primary , Ndpoint ,